Jeffrey Landau
Corporate Officer/Principal chez CYTOMX THERAPEUTICS, INC.
Fortune : 256 673 $ au 31/03/2024
Profil
Jeffrey Landau is currently the Chief Business Officer, Senior VP & Head-Strategy at CytomX Therapeutics, Inc. He previously worked as the Vice President-Business Development at Catalyst Biosciences, Inc. from 2016 to 2021.
Prior to that, he was the Director-Corporate Development & Marketing at Threshold Pharmaceuticals, Inc. Mr. Landau has an undergraduate degree from Virginia Polytechnic Institute & State University and an MBA from Stanford Graduate School of Business.
Détentions connues dans des sociétés publiques
| Société | Date | Nombre d'actions | Valorisation | Date de valorisation |
|---|---|---|---|---|
| 19/03/2024 | 117 740 ( 0,17% ) | 256 673 $ | 31/03/2024 |
Postes actifs de Jeffrey Landau
| Sociétés | Poste | Début |
|---|---|---|
| CYTOMX THERAPEUTICS, INC. | Corporate Officer/Principal | 01/04/2021 |
Anciens postes connus de Jeffrey Landau
| Sociétés | Poste | Fin |
|---|---|---|
| CATALYST BIOSCIENCES | Corporate Officer/Principal | 01/03/2021 |
Threshold Pharmaceuticals, Inc.
 Threshold Pharmaceuticals, Inc. BiotechnologyHealth Technology Threshold Pharmaceuticals, Inc. engages in the development of therapeutics for treating tumors. It offers the Evofosfamide which designed as a prodrug that is activated under the extreme hypoxic conditions commonly found in tumors, but not typically in healthy tissues, and TH-3424 which is a small-molecule drug candidate for the treatment of liver, castrate resistant prostate cancer, T-cell acute lymphoblastic leukemias, and other cancers. The company was founded by Jeffrey W. Bird on October 17, 2001 and is headquartered in South San Francisco, CA | Sales & Marketing | - |
Formation de Jeffrey Landau
| Virginia Polytechnic Institute & State University | Undergraduate Degree |
| Stanford Graduate School of Business | Masters Business Admin |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Sociétés cotées | 1 |
|---|---|
| CYTOMX THERAPEUTICS, INC. | Health Technology |
| Entreprise privées | 2 |
|---|---|
Threshold Pharmaceuticals, Inc.
Threshold Pharmaceuticals, Inc. BiotechnologyHealth Technology Threshold Pharmaceuticals, Inc. engages in the development of therapeutics for treating tumors. It offers the Evofosfamide which designed as a prodrug that is activated under the extreme hypoxic conditions commonly found in tumors, but not typically in healthy tissues, and TH-3424 which is a small-molecule drug candidate for the treatment of liver, castrate resistant prostate cancer, T-cell acute lymphoblastic leukemias, and other cancers. The company was founded by Jeffrey W. Bird on October 17, 2001 and is headquartered in South San Francisco, CA | Health Technology |
Catalyst Biosciences, Inc.
 Catalyst Biosciences, Inc. BiotechnologyHealth Technology Catalyst Biosciences, Inc. operates as a clinical-stage biopharmaceutical company. It engages in the development of novel medicines to address serious medical conditions. The company was founded on March 7, 1997 and is headquartered in South San Francisco, CA. | Health Technology |
